ACOR — Acorda Therapeutics Share Price
Last trade - 00:00- $21.51m
- $160.72m
- $152.97m
- 46
- 84
- 21
- 51
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.13 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.67% | ||
| Return on Equity | -69.64% | ||
| Operating Margin | -111.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 519.6 | 588.29 | 471.43 | 192.41 | 152.97 | 120.38 | 120.52 | -20.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.
Directors
- John Kelley NEC (67)
- Ron Cohen CEO (65)
- Michael Gesser CFO (59)
- Lauren Sabella COO (60)
- Neil Belloff GCN (62)
- Kerry Clem OTH
- John Varian DRC (60)
- Peder Jensen IND (66)
- Sandra Panem IND (74)
- Lorin Randall IND (77)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- March 17th, 1995
- Public Since
- February 10th, 2006
- No. of Shareholders
- 16
- No. of Employees
- 167
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 11,202,242
- Address
- 420 Saw Mill River Rd, ARDSLEY, 10502-2605
- Web
- http://www.acorda.com
- Phone
- +1 9143474300
- Auditors
- Ernst & Young LLP
Latest News for ACOR
Upcoming Events for ACOR
Q4 2021 Acorda Therapeutics Inc Earnings Release
Q1 2022 Acorda Therapeutics Inc Earnings Release
Acorda Therapeutics Inc Annual Shareholders Meeting
Similar to ACOR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
ACADIA Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 01:14 UTC, shares in Acorda Therapeutics are trading at $1.92. This share price information is delayed by 15 minutes.
Shares in Acorda Therapeutics last closed at $1.92 and the price had moved by -76.12% over the past 365 days. In terms of relative price strength the Acorda Therapeutics share price has underperformed the S&P500 Index by -79.7% over the past year.
The overall consensus recommendation for Acorda Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acorda Therapeutics does not currently pay a dividend.
Acorda Therapeutics does not currently pay a dividend.
Acorda Therapeutics does not currently pay a dividend.
To buy shares in Acorda Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.92, shares in Acorda Therapeutics had a market capitalisation of $21.51m.
Here are the trading details for Acorda Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACOR
Based on an overall assessment of its quality, value and momentum Acorda Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acorda Therapeutics is $10.00. That is 420.83% above the last closing price of $1.92.
Analysts covering Acorda Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$7.64 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acorda Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -60.4%.
As of the last closing price of $1.92, shares in Acorda Therapeutics were trading -50.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Acorda Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Acorda Therapeutics' management team is headed by:
- John Kelley - NEC
- Ron Cohen - CEO
- Michael Gesser - CFO
- Lauren Sabella - COO
- Neil Belloff - GCN
- Kerry Clem - OTH
- John Varian - DRC
- Peder Jensen - IND
- Sandra Panem - IND
- Lorin Randall - IND